This meeting took place in the past. Here is a list of meetings that are related:
Advances in Checkpoints Immunology from Autoimmunity to Oncology to Infectious Diseases (2022B1)
Web Desc
Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity
Organizer(s): Daniel J. Cua, E. John Wherry and Carla V. Rothlin
Date: February 18 - 22, 2019
Location: Beaver Run Resort, Breckenridge, CO, USA
Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Organized in collaboration with Cancer Research UK

Sponsored by AbbVie Inc., BioLegend, Inc., Compass Therapeutics, EMD Serono Research and Development Institute, Inc., Genentech, Inc., Incyte Corporation, MacroGenics, Inc., Merck & Co., Inc., MorphoSys AG, Pfizer Inc., Roche, Surface Oncology, Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.
Summary of Meeting:
Significant progress has been made in the field of immunology over the past two decades. Therapeutic agents such as anti-TNF, anti-CD20, anti-CTLA4, and more recently, anti-PD1 have benefited countless patients. This is a unique time for immunologists and clinical scientists to learn from the sheer number of clinical trials assessing immune targets for treatment of cancer and autoimmunity. Currently, there are more than 500 clinical studies testing combinations of checkpoint inhibitors with other pathway antagonists, which will begin to uncover the “immune mechanisms” driving the disease process. This is highlighted by the observation that more than 10-20% of patients treated with anti-PD1 and/or CTLA4 later suffer from autoimmunity (e.g., anti-PD1 treatment is linked to Type 1 diabetes and anti-CTLA-4 treatment is linked to inflammatory bowel disease). Response rate to cancer treatment is greater in patients with autoimmune predisposition; therefore the autoimmune side effect is in part associated with patient genetics. The meeting topics will include discussions of combination immunotherapies, the genetics of patient response, and strategies to reprogram adaptive and innate immunity, which are key to harnessing the immune system to fight cancer and autoimmune diseases. The meeting will end with a special closing lecture on the future of immunotherapy.
Scholarship Deadline: October 23 2018
Discounted Abstract Deadline: October 23 2018
Abstract Deadline: November 15 2018
Discounted Registration Deadline: December 18 2018
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AbbVie Inc.BioLegend, Inc.Organized in collaboration with Cancer Research UKCompass TherapeuticsEMD Serono Research and Development Institute, Inc.Genentech, Inc.Incyte CorporationMacroGenics, Inc.Merck & Co., Inc.MorphoSys AGPfizer Inc.RocheSurface OncologyTakeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company LimitedTessa Therapeutics Ltd.
We gratefully acknowledge additional support from these exhibitors at this conference:
AYOXXA Biosystems GmbH
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)eLife
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Dynavax Technologies Corporation

Genentech, Inc.

Merck & Co., Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA232437-01
Funding for this conference was made possible (in part) by 1 R13 CA232437-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Monday, February 18 | 4:00PM - 8:00PM
Arrival and Registration
Room: Colorado Ballroom Foyer


Monday, February 18 | 6:00PM - 8:00PM
Welcome Mixer
Room: Colorado Ballroom Foyer
No registration fees are used to fund alcohol served at this function.

Tuesday, February 19 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Tuesday, February 19 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Colorado Ballroom

Speaker 1 of 2
* Daniel J. Cua, Janssen Pharmaceutical Companies of Johnson & Johnson, USA

Tuesday, February 19 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Colorado Ballroom

Speaker 2 of 2
Arlene H. Sharpe, Harvard Medical School, USA
Checkpoint Blockade for Cancer Immunotherapy

Tuesday, February 19 | 9:00AM - 11:15AM
Checkpoint Blockade Predisposes Patients to Autoimmunity
Room: Colorado Ballroom


Speaker 1 of 6
* E. John Wherry, University of Pennsylvania, USA

Tuesday, February 19 | 9:00AM - 11:15AM
Checkpoint Blockade Predisposes Patients to Autoimmunity
Room: Colorado Ballroom


Speaker 2 of 6
Jeffrey A. Bluestone, University of California, San Francisco, USA
Development of Syngeneic NOD Tumor Models to Study Tumor Immunity in Autoimmune-Prone Mice

Tuesday, February 19 | 9:00AM - 11:15AM
Checkpoint Blockade Predisposes Patients to Autoimmunity
Room: Colorado Ballroom



Coffee Break

Tuesday, February 19 | 9:00AM - 11:15AM
Checkpoint Blockade Predisposes Patients to Autoimmunity
Room: Colorado Ballroom


Speaker 4 of 6
Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Immune Mechanisms Influencing Checkpoint Therapy

Tuesday, February 19 | 9:00AM - 11:15AM
Checkpoint Blockade Predisposes Patients to Autoimmunity
Room: Colorado Ballroom


Speaker 5 of 6
Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Regulation of Autoimmunity and Cancer by PD1 and LAG3

Tuesday, February 19 | 9:00AM - 11:15AM
Checkpoint Blockade Predisposes Patients to Autoimmunity
Room: Colorado Ballroom


Speaker 6 of 6
Soyoung Oh, Genentech, Inc., USA
Short Talk: PD-L1 Expression by Dendritic Cells Is a Critical Checkpoint in the Regulation of T Cell Immunity

Tuesday, February 19 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, February 19 | 11:15AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Tuesday, February 19 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom


Tuesday, February 19 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Tuesday, February 19 | 5:00PM - 7:00PM
Genetics of Autoimmunity and Cancer: What are the Common Den
ominators?

Room: Colorado Ballroom

Speaker 1 of 5
* Carla V. Rothlin, Yale University, USA

Tuesday, February 19 | 5:00PM - 7:00PM
Genetics of Autoimmunity and Cancer: What are the Common Den
ominators?

Room: Colorado Ballroom

Speaker 2 of 5
Alex Marson, University of California, San Francisco, USA
Reprogramming Human Immune Cell Circuitry

Tuesday, February 19 | 5:00PM - 7:00PM
Genetics of Autoimmunity and Cancer: What are the Common Den
ominators?

Room: Colorado Ballroom

Speaker 3 of 5
Elissa K. Deenick, Garvan Institute of Medical Research, Australia
Signals Controlling Lymphocyte Activation and Autoimmunity - Lessons from Inborn Errors of Immunity

Tuesday, February 19 | 5:00PM - 7:00PM
Genetics of Autoimmunity and Cancer: What are the Common Den
ominators?

Room: Colorado Ballroom

Speaker 4 of 5
Wenjun Ouyang, Amgen, Inc., USA
Population to Population Strategies to Identify Novel Regulatory Pathways for T Cells

Tuesday, February 19 | 5:00PM - 7:00PM
Genetics of Autoimmunity and Cancer: What are the Common Den
ominators?

Room: Colorado Ballroom

Speaker 5 of 5
Zia Khan, Genentech, Inc., USA
Short Talk: Genetic Risk for Skin Autoimmunity Impacts the Safety and Efficacy of Immune Checkpoint Blockade in Urothelial Carcinoma

Tuesday, February 19 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Tuesday, February 19 | 7:30PM - 10:00PM
Poster Session 1
Room: Breckenridge Ballroom


Wednesday, February 20 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 1 of 8
* Susan M. Kaech, The Salk Institute, USA

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 2 of 8
Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Treg Stability in Disease

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 3 of 8
Mark S. Anderson, University of California, San Francisco, USA
Modulating Self-Tolerance in Autoimmunity and Cancer

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom


Coffee Break

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 5 of 8
Maria Grazia Roncarolo, Stanford University School of Medicine, USA
Regulatory T Cell Therapy in Cancer and Autoimmunity

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 6 of 8
Eric Meffre, Yale University School of Medicine, USA
Impaired B Cell Tolerance and Autoimmunity: CTLA-4 Blockade Dirty Secret

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 7 of 8
Theodore T. Drashansky, University of Florida, USA
Short Talk: Epigenetic Landscape Dictated by Bcl11b Sustains Treg Cell Program while Blocking Innate Lineage and Apoptosis

Wednesday, February 20 | 8:00AM - 11:00AM
Cellular Reprogramming: Regulatory vs. Functional Fate
Room: Colorado Ballroom

Speaker 8 of 8
Sophie Lucas, de Duve Institute, Belgium
Short Talk: Structural Basis of Latent TGF-ß1 Presentation and Activation by GARP on Human Regulatory T Cells

Wednesday, February 20 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, February 20 | 11:00AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Wednesday, February 20 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom


Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 1 of 9
* Soyoung Oh, Genentech, Inc., USA

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 2 of 9
Peter V. Kharchenko, Harvard Medical School, USA
Molecular Impact of Prostate Cancer Metastasis on the Bone Marrow Microenvironment

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 3 of 9
Kasey L. Couts, University of Colorado Denver, USA
Differential Gene Expression Across Melanoma Subtypes Predicts Responses to Immune Checkpoint Blockade

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 4 of 9
Yannick Simoni, Fred Hutchinson Cancer Research Center, USA
Identification of Tumor-Specific CD8+ T Cells in EBV-Driven Lymphoephitelioma-Like Carcinoma: A Case Report

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 5 of 9
Colt Egelston, City of Hope, USA
Identification of Tumor Inflammation-Associated Exhausted CD8+ T Cells in Breast Cancer Patients

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 6 of 9
Alexander Huang, University of Pennsylvania, USA
Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 7 of 9
Debattama Sen, Massachusetts General Hospital, USA
Functionally Specialized Subsets of Exhausted CD8+ T Cells Mediate Tumor Control and Differentially Respond to Checkpoint Blockade

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 8 of 9
* Krijn Dijkstra, Netherlands Cancer Institute, Netherlands
Generation of Tumor-Reactive T Cells by Co-Culture of Peripheral Blood Lymphocytes and Tumor Organoids

Wednesday, February 20 | 2:30PM - 4:30PM
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapi
es
Room: Colorado Ballroom

Speaker 9 of 9
Martina Damo, Yale University, USA
A New Mouse Model to Investigate Tissue-Specific Aspects of Peripheral T Cell Tolerance

Wednesday, February 20 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Wednesday, February 20 | 5:00PM - 7:00PM
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell
Lineages

Room: Colorado Ballroom

Speaker 1 of 6
* Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA

Wednesday, February 20 | 5:00PM - 7:00PM
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell
Lineages

Room: Colorado Ballroom

Speaker 2 of 6
E. John Wherry, University of Pennsylvania, USA
T Cell Exhaustion and Fate Decisions – Implications for Immunotherapy

Wednesday, February 20 | 5:00PM - 7:00PM
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell
Lineages

Room: Colorado Ballroom

Speaker 3 of 6
Ian A. Parish, Peter MacCallum Cancer Centre, Australia
Phenotypically and Functionally Defining CD8+ T Cell Tolerance versus Exhaustion

Wednesday, February 20 | 5:00PM - 7:00PM
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell
Lineages

Room: Colorado Ballroom

Speaker 4 of 6
W. Nicholas Haining, Merck Research Laboratories, USA
Epigenetic Engineering of Tumor Immunity

Wednesday, February 20 | 5:00PM - 7:00PM
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell
Lineages

Room: Colorado Ballroom

Speaker 5 of 6
Shin Foong Ngiow, University of Pennsylvania, USA
Short Talk: Lag3 Represses Cytotoxicity Program to Facilitate CD8 T Cell Exhaustion

Wednesday, February 20 | 5:00PM - 7:00PM
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell
Lineages

Room: Colorado Ballroom

Speaker 6 of 6
Kristen Elaine Pauken, Harvard Medical School, USA
Short Talk: Deletion of PD-1 Promotes Anti-Tumor Immunity through Cell Intrinsic and Extrinsic Improvements in CD8+ T Cell Metabolism and Functions

Wednesday, February 20 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Wednesday, February 20 | 7:30PM - 10:00PM
Poster Session 2
Room: Breckenridge Ballroom


Thursday, February 21 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 1 of 8
* Catherine Hedrick, La Jolla Institute for Immunology, USA

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 2 of 8
Mikael J. Pittet, Massachusetts General Hospital, USA
Myeloid Cells in Cancer Therapies

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 3 of 8
Carla V. Rothlin, Yale University, USA
Coincidence Detectors in Macrophages and Tissue Repair

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom


Coffee Break

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 5 of 8
Ming O. Li, Memorial Sloan Kettering Cancer Center, USA
Deconstructing the Antigen-Presenting Cell Compartment in Cancer

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 6 of 8
Nathaniel R. West, Genentech, Inc., USA
Host Genetics, Cytokines, and Dysbiosis in the Regulation of Chronic Intestinal Inflammation and Cancer

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 7 of 8
Hind Medyouf, Institute for Tumor Biology and Experimental Therapy, Germany
Short Talk: Targeting TAM Receptors Unleashes Anti-Leukemic Immunity and Enables Checkpoint Blockade Leading to Eradication of Leukemic Cells

Thursday, February 21 | 8:00AM - 11:00AM
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Room: Colorado Ballroom

Speaker 8 of 8
Sergei Grivennikov, Fox Chase Cancer Center, USA
Short Talk: Cell Type Specific Role of Cytokines in Control of Tumor Promoting Inflammation and Tumor Bacterial Invasion

Thursday, February 21 | 11:00AM - 5:00PM
On Own for Lunch


Thursday, February 21 | 11:00AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Thursday, February 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom


Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 1 of 9
* Hind Medyouf, Institute for Tumor Biology and Experimental Therapy, Germany

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 2 of 9
Yemsratch T. Akalu, Yale University School of Medicine, USA
An eMERerging Target in Cancer Immunotherapy

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 3 of 9
Joanne Tan, Arcus Biosciences, USA
Targeting Innate Immune Cells for the Treatment of Cancer

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 4 of 9
Tal Burstyn-Cohen, Hebrew University Jerusalem, Israel
Myeloid-Derived PROS1 Inhibits Tumor Metastasis by Curbing Inflammation

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 5 of 9
Chang-Yu Chen, Tokyo University of Science, Japan
An Alarmin HMGN1 Synergizes with PD-L1 Blockade and CD4 Depletion to Reinforce CD8 T Cell-Mediated Anti-Tumor Immunity

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 6 of 9
* Kelsey E. Sivick Gauthier, Arcus Biosciences, Inc., USA
Magnitude of Therapeutic STING Activation Critically Impacts CD8+ T Cell-Mediated Anti-Tumor Immunity

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 7 of 9
Karen Hastings, University of Arizona College of Medicine, USA
High GILT Expression and an Active and Functional MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 8 of 9
Emma Lo Kuan, Benaroya Research Institute, USA
Thymic Stromal Lymphopoietin Promotes Interplay between Tumor Cells, Myeloid Cells, and CD8+ T Cells in Regulation of Breast Cancer

Thursday, February 21 | 2:30PM - 4:30PM
Workshop 2: Latest Developments on the Role of Myeloid Cells
in Inflammation and Cancer
Room: Colorado Ballroom

Speaker 9 of 9
Rachel S. Friedman, National Jewish Health and University of Colorado Denver, USA
Mononuclear Phagocytes Drive a Mertk-Dependent Tolerance Checkpoint at the Autoimmune Disease Site

Thursday, February 21 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 1 of 7
* Carla V. Rothlin, Yale University, USA

Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 2 of 7
Matthew F. Krummel, University of California, San Francisco, USA
Archetypes of Immunity and Myeloid Tuning Immunotherapies

Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 3 of 7
Catherine Hedrick, La Jolla Institute for Immunology, USA
Neutrophil Heterogeneity in Cancer

Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 4 of 7
Susan M. Kaech, The Salk Institute, USA
Nutrient Regulation of Anti-Tumor Immunity

Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 5 of 7
Dmitry I. Gabrilovich, AstraZeneca, USA
Neutrophils and PMN-MDSC in Cancer: Two Sides of Functional Diversity

Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 6 of 7
James T. Nevin, University of Connecticut Health Center, USA
Short Talk: Sympathetic Nervous Tone Influences Accumulation of Myeloid-Derived Suppressor Cells and Immune Control of Tumor Growth

Thursday, February 21 | 5:00PM - 7:30PM
Neutrophils and MDSCs in Host Defense and Cancer
Room: Colorado Ballroom

Speaker 7 of 7
Eynav Klechevsky, Washington University School of Medicine, USA
Short Talk: Upstream Regulation of Autoimmunity and Cancer via Human Dendritic Cell Subsets

Thursday, February 21 | 7:30PM - 8:30PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, February 21 | 7:30PM - 10:00PM
Poster Session 3
Room: Breckenridge Ballroom


Friday, February 22 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 1 of 8
* Daniel J. Cua, Janssen Pharmaceutical Companies of Johnson & Johnson, USA

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 2 of 8
Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Checkpoint Inhibition

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 3 of 8
Alan J. Korman, Vir Biotechnology, Inc., USA
An Acidic pH Selective Pathway for Immune Regulation

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom


Coffee Break

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 5 of 8
Emmett V. Schmidt, Merck Research Labs, USA
Developing Combination Strategies using PD-1 Checkpoint Inhibitors to Treat Cancer

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 6 of 8
Robert L. Coffman, Dynavax Technologies, USA
Expanding the Potential of Cancer Immunotherapy with TLR9 Agonists

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 7 of 8
Leonardo Ferreira, University of California, San Francisco, USA
Short Talk: Chimeric Antigen Receptors for Dissecting Treg Biology and Next-Gen Treg Therapy

Friday, February 22 | 8:00AM - 11:00AM
Finding the Cure for Cancer
Room: Colorado Ballroom

Speaker 8 of 8
Lisa Cucolo, University of Pennsylvania, USA
Short Talk: Tumor RIPK1 Signaling Mediates Intrinsic and Extrinsic Mechanisms of Resistance to Immune Checkpoint Blockade Therapy

Friday, February 22 | 11:00AM - 5:00PM
On Own for Lunch


Friday, February 22 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Friday, February 22 | 5:00PM - 6:45PM
Integrated Themes across Preclinical and Clinical Treatment
of Cancer and Autoimmunity

Room: Colorado Ballroom

Speaker 1 of 4
* Maria Grazia Roncarolo, Stanford University School of Medicine, USA

Friday, February 22 | 5:00PM - 6:45PM
Integrated Themes across Preclinical and Clinical Treatment
of Cancer and Autoimmunity

Room: Colorado Ballroom

Speaker 2 of 4
Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
The Role of CD39 in the Immunological Control of Cancer

Friday, February 22 | 5:00PM - 6:45PM
Integrated Themes across Preclinical and Clinical Treatment
of Cancer and Autoimmunity

Room: Colorado Ballroom

Speaker 3 of 4
Daniel J. Cua, Janssen Pharmaceutical Companies of Johnson & Johnson, USA
Applying Lessons from Autoimmune Inflammation to Immuno-Oncology

Friday, February 22 | 5:00PM - 6:45PM
Integrated Themes across Preclinical and Clinical Treatment
of Cancer and Autoimmunity

Room: Colorado Ballroom

Speaker 4 of 4
Hergen Spits, University of Amsterdam, Netherlands
Anti-Tumor B Cell Responses in Cancer Patients Responding to Immunotherapy

Friday, February 22 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions
Room: Colorado Ballroom

Speaker 1 of 1
* Hergen Spits, University of Amsterdam, Netherlands

Friday, February 22 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Friday, February 22 | 8:00PM - 11:00PM
Entertainment
Room: Breckenridge Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Friday, February 22 | 8:00PM - 11:00PM
Cash Bar
Room: Breckenridge Ballroom


Saturday, February 23 | 10:24AM - 10:24AM
Departure


*Session Chair.